Pioneering and advancing treatments for severe inflammation and autoimmune diseases by selectively targeting shared critical pathways driving disease pathogenesis. Lead program, Inebilizumab, is a CD19 mAb which met the primary endpoint in the Ph 2b pivotal study for the treatment of Neuromyelitis Optica. Primary analysis demonstrated a 77% reduction in the risk of developing NMOSD attack in patients treated with inebilizumab monotherapy compared to placebo. BLA filing expected mid-2019. Full global rights to 6 assets (4 clinical, 2 preclinical) from AstraZeneca/Medimmune.
Phase III, Phase l or ll
One MedImmune Way
Fifth Floor, Suite Area Two
Gaithersburg, MD 20878
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Upcoming Company Event Participation
Solebury Trout Management Access: SF 2020
San Francisco, CA, United States,
January 13 –
January 16, 2020
Stock Market Data
Market Data copyright © 2019 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by